CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 12.29: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.13BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.4190xvs all stocks
52-Week Change
210.05%vs all stocks
Market Capitalization
1.13BUSDvs all stocks (USD)
Enterprise Value
861.98MUSDvs all stocks (USD)
Forward P/E
-30.27xvs Biotechnology peers
Price to Book (MRQ)
4.02xvs Biotechnology peers
Enterprise to EBITDA
-7.31xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-31.23%vs Biotechnology peers
Return on Equity (TTM)
-56.40%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 18, 2026Gross Profit (TTM)
-92.92MUSDvs all stocks (USD)
EBITDA (TTM)
-117.91MUSDvs all stocks (USD)
Net Income (TTM)
-114.59MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-92.63MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-70.47MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-108.14MUSDvs all stocks (USD)
Pre-tax Income
-105.04MUSDFY2025 · Dec 31, 2025Income Tax Expense
1.60KUSDFY2025 · Dec 31, 2025Net Income
-105.04MUSDFY2025 · Dec 31, 2025EBIT
-102.00MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-106.21MUSDFY2025 · Dec 31, 2025Research & Development
84.45MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
22.75MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
3.05MUSDFY2025 · Dec 31, 2025EPS (Basic)
-2.26USDFY2025 · Dec 31, 2025EPS (Diluted)
-2.26USDFY2025 · Dec 31, 2025Basic Shares Outstanding
46.48MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
46.48MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-105.04MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-71.86MUSDFY2025 · Dec 31, 2025Free Cash Flow
-83.58MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
287.85MUSDFY2025 · Dec 31, 2025Income Tax Paid
1.60KUSDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-105.04MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.89MUSDFY2025 · Dec 31, 2025Stock-based Compensation
17.23MUSDFY2025 · Dec 31, 2025Other Non-cash Items
3.76MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
10.31MUSDFY2025 · Dec 31, 2025Capital Expenditures
-11.72MUSDFY2025 · Dec 31, 2025Purchase of Investments
-151.39MUSDFY2025 · Dec 31, 2025Sale of Investments
260.60MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
97.48MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
237.03MUSDFY2025 · Dec 31, 2025Shares Outstanding
57.66MSharesUpdated Jul 18, 2026Float Shares
48.55MSharesUpdated Jul 18, 2026Shares Short
14.74MSharesUpdated Jul 18, 2026Short Ratio
10.41daysvs all stocks
Short % of Shares Outstanding
28.11%vs all stocks
% Held by Insiders
9.47%vs all stocks
% Held by Institutions
59.63%vs all stocks
Total Cash (MRQ)
278.61MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.81USDUpdated Jul 18, 2026Total Debt (MRQ)
14.78MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0530xvs Biotechnology peers
Current Ratio (MRQ)
8.42xvs Biotechnology peers
Book Value per Share (MRQ)
4.83USDUpdated Jul 18, 2026Total Assets
355.95MUSDvs all stocks (USD)
Total Current Assets
322.94MUSDFY2025 · Dec 31, 2025Total Liabilities
50.16MUSDFY2025 · Dec 31, 2025Total Non-current Assets
33.01MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
14.32MUSDFY2025 · Dec 31, 2025Total Current Liabilities
35.84MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
287.85MUSDFY2025 · Dec 31, 2025Other Short-term Investments
30.28MUSDFY2025 · Dec 31, 2025Accounts Receivable
59.17KUSDFY2025 · Dec 31, 2025Accounts Payable
1.65MUSDFY2025 · Dec 31, 2025Short-term Debt
202.38KUSDFY2025 · Dec 31, 2025Deferred Revenue
12.00MUSDFY2025 · Dec 31, 2025Other Current Liabilities
6.42MUSDFY2025 · Dec 31, 2025Long-term Debt
14.32MUSDFY2025 · Dec 31, 2025Common Stock (Book)
57.37KUSDFY2025 · Dec 31, 2025Retained Earnings
-304.88MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
305.79MUSDvs all stocks (USD)
52-Week Low
4.30USDUpdated Jul 18, 202652-Week High
40.37USDUpdated Jul 18, 202652-Week Change
210.05%vs all stocks
Beta
0.4190xvs all stocks
50-Day MA
26.74USDUpdated Jul 18, 2026200-Day MA
23.03USDUpdated Jul 18, 2026Avg 10-Day Volume
1.38MSharesUpdated Jul 18, 2026Avg 30-Day Volume
1.49MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-2.32USDUpdated Jul 18, 2026Other Income / Expense
6.15MUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 12.29: safe zoneNotable
Altman Z-Score: 12.29
High structural barrier to entryNotable
Barrier to Entry: 4.81
Consistent revenue growth patternNotable
Growth Consistency Score: 1.06
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Savara Inc.
Tier 1ProductionApproval-Gated PipelineRule
Wave Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Gen Ilac ve Saglik Urunleri A.S.
Tier 1ProductionApproval-Gated PipelineRule
Frontier Biotechnologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guangxi Wuzhou Zhongheng Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
China Resources Boya Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
EyePoint Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
SSY Group Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Alvotech S.A.
Tier 1ProductionApproval-Gated PipelineRule
Shinva Medical Instrument Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
3 interpretationsDecline With Range Expansion And DrawdownCash Elevated Relative to Current Liabilities and Total AssetsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Sealsq Corp
3 interpretationsDecline With Range Expansion And DrawdownCash Elevated Relative to Current Liabilities and Total AssetsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Directa Plus Plc
3 interpretationsDecline With Range Expansion And DrawdownCash Elevated Relative to Current Liabilities and Total AssetsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated